Sarah Cannon Research Institute Investigators Author 11 Studies for Presentation at San Antonio Breast Cancer Symposium

Sarah Cannon Research Institute Investigators Author 11 Studies for Presentation at San Antonio Breast Cancer Symposium

Sarah Cannon Research Institute

[email protected]

investigators are authors on 11 clinical trial abstracts accepted for presentation during the , which takes place Dec. 4-8.

“We are excited to share SCRI’s research efforts with our scientific colleagues at this important breast cancer conference,” SCRI Chief Medical Officer said. “The findings are compelling in many cases and demonstrate advances against various breast cancer clinical scenarios our patients face.”

SCRI Senior Investigator, Breast Cancer Research Program, serves as lead author on seven of the 11 studies that will be presented at the meeting. Other SCRI principal investigators who co-authored abstracts to be presented include Dr. Burris, Chief Scientific Officer, and Director of Drug Development . Details are as follows:

The objective of the SABCS is to provide state-of-the-art information on the experimental biology, etiology, prevention, diagnosis, and therapy of breast cancer and premalignant disease, to an international audience of academic and private physicians and researchers. This international symposium is directed primarily towards academic and private physicians and researchers involved in breast cancer in medical, surgical, gynecologic, and radiation oncology, as well as other appropriate health care professionals.

Sarah Cannon Research Institute (SCRI) is a global strategic research organization focusing on advancing therapies for patients. It is one of the largest clinical research programs, conducting community-based clinical trials in oncology and cardiology through affiliations with a network of more than 700 physicians in the United States and United Kingdom. Additionally, SCRI offers management, regulatory and other research support services to drug development sponsors and strategic investigator sites. For more information, please visit .

Suggested Articles

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.

Gilead is hoping to score a patent extension on TAF meds, but patient advocates say that would reward conduct that harmed patients.